Arbutus Biopharma (NASDAQ:ABUS) Earns “Buy” Rating from Chardan Capital

Arbutus Biopharma (NASDAQ:ABUS)‘s stock had its “buy” rating restated by equities researchers at Chardan Capital in a report released on Wednesday, Stock Target Advisor reports. They presently have a $5.00 target price on the biopharmaceutical company’s stock. Chardan Capital’s target price would suggest a potential upside of 43.27% from the stock’s current price.

Other analysts have also recently issued reports about the company. StockNews.com raised Arbutus Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, August 10th. JMP Securities upped their price target on Arbutus Biopharma to $5.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Arbutus Biopharma in a research report on Monday. Finally, Jefferies Financial Group boosted their price objective on Arbutus Biopharma from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday, September 5th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Arbutus Biopharma presently has an average rating of “Moderate Buy” and an average target price of $5.50.

Arbutus Biopharma Trading Down 0.9 %

Shares of NASDAQ:ABUS opened at $3.49 on Wednesday. The stock has a market capitalization of $661.32 million, a P/E ratio of -8.12 and a beta of 1.92. Arbutus Biopharma has a 1-year low of $1.79 and a 1-year high of $4.72. The business has a 50-day moving average price of $3.94 and a two-hundred day moving average price of $3.64.

Hedge Funds Weigh In On Arbutus Biopharma

A number of large investors have recently bought and sold shares of ABUS. Barclays PLC boosted its holdings in shares of Arbutus Biopharma by 466.3% in the 3rd quarter. Barclays PLC now owns 272,029 shares of the biopharmaceutical company’s stock valued at $1,047,000 after buying an additional 223,995 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Arbutus Biopharma by 4.1% in the 3rd quarter. Geode Capital Management LLC now owns 3,448,600 shares of the biopharmaceutical company’s stock valued at $13,280,000 after buying an additional 135,442 shares during the last quarter. XTX Topco Ltd boosted its holdings in shares of Arbutus Biopharma by 76.2% in the 3rd quarter. XTX Topco Ltd now owns 30,013 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 12,975 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Arbutus Biopharma by 4.6% in the 3rd quarter. Wellington Management Group LLP now owns 496,818 shares of the biopharmaceutical company’s stock valued at $1,913,000 after buying an additional 21,807 shares during the last quarter. Finally, State Street Corp boosted its holdings in shares of Arbutus Biopharma by 50.2% in the 3rd quarter. State Street Corp now owns 4,407,133 shares of the biopharmaceutical company’s stock valued at $16,967,000 after buying an additional 1,472,652 shares during the last quarter. Institutional investors and hedge funds own 43.79% of the company’s stock.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.